ZFHX3
ZFHX3 (zinc finger homeobox 3, also known as ATBF1, ZNF927, FLJ26184 and C16orf47) is a large transcription factor with multiple homeodomains and zinc finger motifs. It can act as an activator or a repressor and regulates myogenic and neuronal differentiation. Browse Assay Genie's current range of ZFHX3 research reagents below, or read on for the biology behind the target.
ZFHX3 is a transcriptional regulator that can either activate or repress its targets. It inhibits the enhancer element of the AFP gene by binding to its AT-rich core sequence, and together with SMAD-dependent TGF-beta signalling it can repress AFP transcription through an interaction with SMAD2/3. It also regulates myoblast differentiation by binding the AT-rich sequence of the MYF6 promoter and repressing it, and it down-regulates the MUC5AC promoter in gastric cancer.
In association with RUNX3, ZFHX3 up-regulates CDKN1A promoter activity after TGF-beta stimulation, consistent with the reported transactivation of the cell cycle inhibitor p21CIP1. The protein has also been shown to negatively regulate c-Myb. In ESR1-positive breast cancer cells it inhibits oestrogen receptor function by competing with the coactivator NCOA3 for binding to ESR1. In the suprachiasmatic nucleus of the brain, ZFHX3 regulates circadian locomotor rhythms by activating neuropeptidergic genes needed for intercellular synchrony and rhythm amplitude.
The ZFHX3 gene belongs to the C2H2-type and matrin-type zinc finger groups and to the ZF class homeoboxes. The protein was originally named AT-binding transcription factor 1 (ATBF1), and the gene was previously listed as C16orf47. The gene is reported to function as a tumour suppressor in several cancers, and sequence variants are associated with atrial fibrillation. Multiple transcript variants from alternate promoters encode different isoforms. The mouse ortholog is Zfhx3. Related family member ZFHX4 is a useful comparator in zinc finger homeobox studies.
ZFHX3 is reported to act as a tumour suppressor in several cancers and modulates MUC5AC in gastric cancer and ESR1 function in breast cancer cells.
ZFHX3 activates neuropeptidergic genes in the suprachiasmatic nucleus, supporting intercellular synchrony and rhythm amplitude in circadian locomotor behaviour.
ZFHX3 regulates myoblast differentiation through repression of the MYF6 promoter and is described as a regulator of neuronal differentiation.
Sequence variants of the ZFHX3 gene are associated with atrial fibrillation, making it a candidate for studies of heritable cardiac rhythm disorders.
ZFHX3 is a transcriptional regulator that can activate or repress genes. It represses AFP by binding an AT-rich enhancer motif, represses the MYF6 promoter in myoblasts, and activates neuropeptidergic genes that govern circadian rhythms in the suprachiasmatic nucleus.
ZFHX3 is also called ATBF1 (AT-binding transcription factor 1), ZNF927, FLJ26184 and C16orf47 (chromosome 16 open reading frame 47). Multiple transcript variants from alternate promoters encode different isoforms, so check the datasheet of any product for its validated reactivity.
ZFHX3 is reported to function as a tumour suppressor in several cancers, and sequence variants of the gene are associated with atrial fibrillation. It also inhibits oestrogen receptor function in ESR1-positive breast cancer cells by competing with NCOA3 for ESR1 binding.
Other zinc finger homeobox proteins and transcription factors that work alongside ZFHX3 in differentiation and cancer research.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q15911; product specifications from Assay Genie datasheets.